[211At]methylene blue for targeted radiotherapy of human melanoma xenografts: Dose fractionation in the treatment of cutaneous tumours

European Journal of Cancer Part A

Volumn 32, Issue 7, 1996, Pages 1240-1247

  Link, E M ^a   Carpenter, R N ^b   Hansen, G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

fractionation; melanoma; targeted radiotherapy; 211At methylene blue; particles

Indexed keywords

METHYLENE BLUE;

ALPHA RADIATION; ARTICLE; CANCER RADIOTHERAPY; GENE TARGETING; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN TISSUE; MELANOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0030176150     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00023-8     Document Type: Article

References (35)

1. 1. Kagan R, Witt T, Bines S, Mesleh G, Economou S. Gallium-67 scanning for malignant melanoma. Cancer 1988, 61, 272-274.
2. 32P test and other methods in the diagnosis of intraocular tumours. Doc Ophthalmol 1978, 46, 1-32.
3. 3. Potts AM. Uveal pigment and phenothiazine compounds. Trans Am Ophthalmol Soc 1962, 60, 517-552.
4. 4. Blois MS. On chlorpromazine binding in vivo. J Invest Derm 1965, 45, 475-48.
5. 5. Boyd M, Lieberman LM, Beierwaltes WH, Varma VM. Diagnostic efficacy of a radioiodinated chloroquine analogue in patients with malignant melanoma. J Nucl Med 1970, 11, 479-486.
6. 6. Lindquist NG. Accumulation of drugs on melanin. Acta Radiol 1973, 325 (Suppl.), 1-92.
7. 7. Lyden A, Larsson B, Lindquist NG. Studies on the melanin affinity of haloperidol. Arch Int Pharm Ther 1982, 259, 230-243.
8. 8. Packer S, Redvanly C, Lambrecht RM, Wolf AP, Atkins HL. Quinoline analogue labeled with iodine-123. Arch Ophthalmol 1975, 93, 504-508.
9. 9. Patil PN. Cocaine-binding by the pigmented and the non-pigmented iris and its relevance to the hydriatic effect. Invest Ophthalmol 1972, 11, 739-746.
10. 10. Potts AM. The reaction of uveal pigment in vitro with polycyclic compounds. Invest Opthalmol 1964, 3, 405-416.
11. 11. Coderre JA, Glass JD, Fairchild RG, Roy U, Cohen S, Fand I. Selective targeting of boronophenylalanine to melanoma BALB/c mice for neutron capture therapy. Cancer Res 1987, 47, 6377-6383.
12. 12. Olander K, Larsson B, Dencker L. Thioamides as false melanin precursors: studies in murine melanomas. Acta Pharmacol Toxicol 1983, 52, 135-142.
13. 13. Larson SM. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. Radiology 1987, 165, 297-304.
14. 14. Siccardi AG, Buraggi GL, Callegaro L, et al. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 1986, 46, 4817-4822.
15. 15. Wraight EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 1992, 65, 112-118.
16. 10B molecule-melanoma cell interaction from in vitro to first clinical trial. Pigment Cell Res 1989, 2, 226-234.
17. 17. Fairchild RG, Slatkin DN, Coderre JA, et al. Optimization of boron and neutron delivery for neutron capture therapy. Pigment Cell Res 1989, 2, 309-318.
18. 18. Link EM, Rydzy M. Endoirradiation of neoplastic tissues by administered radioisotopes. In Proc Third Meeting Polish Biophys. Soc. 1978, 62.
19. 19. Dubois D, Ledermann JA, Link EM, Stauss H, Collins M. Malignant melanoma. Lancet 1992, 340, 948-951.
20. 20. Link EM, Lukiewicz S. A new radioactive drug selectively accumulating in melanoma cells. Eur J Nucl Med 1982, 7, 469-473.
21. 211At-methylene blue for pigmented melanoma in an animal model system. Cancer Res 1989, 49, 4332-4337.
22. 22. Link EM, Costa DC, Lui D, Ell PJ, Blower PJ, Spittle MS. Targeting disseminated melanoma with radiolabelled methylene blue: comparative bio-distribution studies in man and animals. Acta Oncol, in press.
23. 23. Reynolds JEF, ed. Martindale - The Extra Pharmacopoeia, 28th edn. London, The Pharmaceutical Press, 1982, 384-385.
24. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases. Cancer Res 1990, 50, 2963-2967.
25. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases. Cancer Res 1992, 52, 4385-4390.
26. 26. Thomas JM. A lung colony clonogenic cell assay from human malignant melanoma in immune-suppressed mice and its use to determine chemosensitivity, radiosensitivity and the relationship between tumour size and response to therapy. Br J Surg 1979, 66, 696-700.
27. 27. West CML, Sandhu RR, Stratford IJ. The radiation response of V79 and human tumour multicellular spheroids - cell survival and growth delay studies. Br J Cancer 1984, 50, 143-151.
28. 28. Cobb LM, Harrison A, Butter SA. Toxicity of astatine-211 in the mouse. Human Toxicol 1988, 7, 529-534.
29. 29. Armitage P. Statistical Methods in Medical Research. Oxford, Blackwell, 1980.
30. 30. Lukiewicz S, Pilas B, Nowicka J, Cieszka K, Gurbiel R. Molecular and cellular basis of different radiosensitivity in pigmented and nonpigmented hamster melanoma cells. In Seiji M, ed. Phenotypic Expression in Pigmented Cells. Tokyo University Press, 1980, 647-653.
31. 31. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1970, 31, 83-833.
32. 32. Adams JS, Habeshaw T, Kirk J. Response rate of malignant melanoma to large fraction irradiation. Br J Radiol 1982, 55, 605-607.
33. 33. Overgaard J. Radiation treatment of malignant melanoma. Int J Radiat Oncol Biol Phys 1980, 6, 41-44.
34. 34. Rumke Ph, van Everdingen JJE. Consensus on the management of melanoma of the skin in the Netherlands. Eur J Cancer 1991, 28, 600-604.
35. 211At-methylene blue in targeted radiotherapy of disseminated melanoma. Pigment Cell Res 1994, 7, 358-362.